Phaseline

Companies › Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MK-1406/CD388
Antifungal vaccine candidate (1,3-β-glucan based immunotherapeutic)
–Phase 3Influenza; Healthy ParticipantsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07300085MK-1406/CD388Phase 1Healthy ParticipantsInfectious diseaseDec 2026
NCT07159763MK-1406/CD388Phase 3InfluenzaInfectious diseaseJun 2027
NCT07225959MK-1406/CD388Phase 2Healthy ParticipantsInfectious diseaseJul 2027

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma MicuRx Jiangxi Qingfeng Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.